Gaballa, Mahmoud R.
Ma, Junsheng
Rauf, Mikael
Bassett, Roland http://orcid.org/0000-0002-4534-2042
Pasvolsky, Oren
Tanner, Mark R.
Bashir, Qaiser http://orcid.org/0000-0002-4086-6453
Srour, Samer A.
Saini, Neeraj
Ramdial, Jeremy
Nieto, Yago
Murphy, Regan
Rezvani, Katayoun
Tang, Guilin http://orcid.org/0000-0002-9482-4806
Lin, Pei
Lee, Hans C. http://orcid.org/0000-0001-8545-3292
Patel, Krina K.
Ullah, Muhammad R.
Kaufman, Gregory P.
Manasanch, Elisabet E. http://orcid.org/0000-0002-0857-176X
Kebriaei, Partow http://orcid.org/0000-0002-8607-9404
Thomas, Sheeba K.
Weber, Donna M.
Shpall, Elizabeth J.
Champlin, Richard E. http://orcid.org/0000-0002-4314-5037
Orlowski, Robert Z.
Qazilbash, Muzaffar H. http://orcid.org/0000-0003-2876-2886
Article History
Received: 28 February 2022
Revised: 21 April 2022
Accepted: 25 April 2022
First Online: 6 May 2022
Ethics approval and patient consent statement
: This retrospective chart review was completed following approval by the MD Anderson Institutional Review Board and in accordance with the Declaration of Helsinki and the 1996 Health Insurance Portability and Accountability Act guidelines.
: MHQ has research support from Janssen, Angiocrine, NexImmune, and Amgen, and consulting or advisory board with Bioclinica, Bristol–Myers Squib, and Oncopeptides. QB has research support from Stemline, Acrotech, and Takeda, and consulting or advisory board with Takeda, KITE, Amgen, Purdue, and Stemline. YN has research support from Astra Zeneca, Affimed, Novartis, and Secura Bio, and consulting with Affimed. KR has research support from Pharmacyclics and Affimed, personal fees and/or advisory board with Gemoab, AvengeBio, Virogin, GSK, Navan Technologies, and Bayer, and a patent license, royalties, and research agreement from Takeda for work outside of this study. HCL has research support and/or consulting with Daiichi Sankyo, Regeneron, Amgen, Celgene, Janssen, Takeda, GSK, Genentech, Sanofi, BMS, Immunitas Legend Biotech, Oncopeptides, and Karyopharm. KKP has research support and/or consulting from Abbvie, Cellectis, Poseida Therapeutics, Bristol–Myers Squibb, Arcellx, Precision Biosciences, Nektar, Takeda, Celgene, Janssen, and Oncopeptides. GPK has research support from BMS and Janssen, and consulting or advisory board with Karyopharm. EEM has research support from Merck, JW Pharma, Novartis, Quest Diagnostics, and Sanofi, and consulting with Adaptive Biotechnologies, GSK, Sanofi, BMS, and Takeda. PK has research support from Ziopharm and Amgen, and consulting or advisory board with Jazz, Pfizer, Novartis, and KITE. SKT has research support from Genentech, Xencor, Acerta, X4 Pharma, Ascentage Pharma and BMS, and advisory board/board of directors with Beigen, Pharmacyclics, and X4 Pharma. RZO is a founder of Asylia Therapeutics, research support from BioTheryX, CARsgen Therapeutics, Exelixis, Celgene, Janssen, Sanofi, and Takeda, and consulting/advisory board with STATinMED, Sanofi, Servier, Takeda, Amgen, Astra Zeneca, BMS, Celgene, EcoR1 Capital, Genzyme, Forma Therapeutics, GSK, Ionis, Janssen, Juno Therapeutics, KITE, Legend Biotech, Regeneron, and Molecular Partners. EJS is co-inventor for a patent licensed to Takeda and advisory board/consulting with Adaptimmune, Axio, Navan, Novartis, and Magenta. The other authors have not declared a competing interest.